The rise of personalized medicine has transformed healthcare by offering genetic testing and treatments tailored to an individual’s biological profile. A key debate, however, is whether the costs of these innovations should be borne by individuals or supported through public healthcare systems.
If individuals are required to cover the costs, personalized medicine could become available only to those who can afford it. This approach risks widening health inequalities, as wealthier patients gain access to more accurate diagnoses and more effective treatments. Ethically, this raises concerns about fairness and justice, since access to essential healthcare would depend on economic status rather than medical need. Additionally, individuals may feel pressured to undergo testing to avoid missing potential health risks, creating a financial burden.
On the other hand, if personalized medicine becomes a public health responsibility, it promotes equal access and supports early detection of diseases, which could reduce long-term healthcare costs. Ethically, this approach aligns with principles of equity and collective wellbeing. However, it raises questions about resource allocation: should limited public funds support expensive individualized treatments when there are other pressing healthcare needs? There is also debate over privacy, as publicly funded systems would need to store and protect large amounts of sensitive genetic data.
In conclusion, both approaches carry significant ethical implications. A balanced solution may involve public funding for essential genetic tests and treatments, while allowing optional or non-critical services to be self-funded. This model supports equity while recognizing economic realities.